See more : Fixstars Corporation (FXSRF) Income Statement Analysis – Financial Results
Complete financial analysis of Immunocore Holdings plc (IMCR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Immunocore Holdings plc, a leading company in the Biotechnology industry within the Healthcare sector.
- Seaboard Corporation (SEB) Income Statement Analysis – Financial Results
- FinecoBank Banca Fineco S.p.A. (FNBKY) Income Statement Analysis – Financial Results
- eREX Co.,Ltd. (ERXCF) Income Statement Analysis – Financial Results
- Rambus Inc. (RMB.DE) Income Statement Analysis – Financial Results
- Fuji Corporation (7605.T) Income Statement Analysis – Financial Results
Immunocore Holdings plc (IMCR)
About Immunocore Holdings plc
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 249.43M | 143.74M | 26.52M | 30.11M | 25.67M | 23.65M |
| Cost of Revenue | 1.04M | 454.00K | 73.23M | 74.81M | 99.99M | 0.00 |
| Gross Profit | 248.39M | 143.28M | -46.71M | -44.70M | -74.32M | 23.65M |
| Gross Profit Ratio | 99.58% | 99.68% | -176.12% | -148.42% | -289.54% | 100.00% |
| Research & Development | 163.55M | 89.17M | 73.23M | 74.81M | 99.99M | 83.58M |
| General & Administrative | 0.00 | 0.00 | 88.40M | 45.74M | 44.18M | 34.16M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 99.99M | 83.58M |
| SG&A | 144.50M | 93.72M | 88.40M | 45.74M | 44.18M | 34.16M |
| Other Expenses | 0.00 | -3.00K | 57.00K | -1.15M | 185.00K | 5.60M |
| Operating Expenses | 308.04M | 182.89M | 161.68M | 119.40M | 144.17M | 117.73M |
| Cost & Expenses | 309.08M | 183.34M | 161.68M | 119.40M | 144.17M | 117.73M |
| Interest Income | 17.99M | 3.15M | 47.00K | 706.00K | 1.40M | 822.00K |
| Interest Expense | 5.15M | 7.69M | 5.81M | 3.11M | 3.80M | 842.00K |
| Depreciation & Amortization | 4.09M | 5.34M | 7.59M | 8.98M | 9.21M | 6.71M |
| EBITDA | -51.65M | -38.35M | -166.72M | -102.59M | -113.18M | -86.75M |
| EBITDA Ratio | -20.71% | -25.36% | -509.48% | -250.54% | -419.63% | -342.21% |
| Operating Income | -59.65M | -39.61M | -135.16M | -86.19M | -118.32M | -93.46M |
| Operating Income Ratio | -23.91% | -27.56% | -509.66% | -286.22% | -460.95% | -395.09% |
| Total Other Income/Expenses | -1.24M | 5.79M | 33.66M | -1.17M | -7.87M | 5.28M |
| Income Before Tax | -60.89M | -44.15M | -140.93M | -87.36M | -126.19M | -88.18M |
| Income Before Tax Ratio | -24.41% | -30.71% | -531.40% | -290.10% | -491.60% | -372.78% |
| Income Tax Expense | -5.60M | -2.92M | -9.41M | -13.27M | -22.26M | -16.55M |
| Net Income | -55.29M | -41.22M | -131.52M | -74.09M | -103.93M | -71.63M |
| Net Income Ratio | -22.17% | -28.68% | -495.94% | -246.04% | -404.89% | -302.82% |
| EPS | -1.13 | -0.90 | -3.10 | -2.33 | -3.81 | -2.62 |
| EPS Diluted | -1.13 | -0.90 | -3.00 | -2.33 | -3.81 | -2.62 |
| Weighted Avg Shares Out | 48.89M | 45.71M | 42.49M | 31.78M | 27.31M | 27.31M |
| Weighted Avg Shares Out (Dil) | 48.89M | 45.71M | 43.86M | 31.78M | 27.31M | 27.31M |
Are Medical Stocks Lagging Immunocore (IMCR) This Year?
What Makes Immunocore Holdings PLC Sponsored ADR (IMCR) a Good Fit for "Trend Investing"
Immunocore to present at the Jefferies London Healthcare Conference
Why Immunocore (IMCR) Might Surprise This Earnings Season
Strength Seen in Immunocore Holdings PLC Sponsored ADR (IMCR): Can Its 10.2% Jump Turn into More Strength?
Wall Street Analysts Believe Immunocore Holdings PLC Sponsored ADR (IMCR) Could Rally 60%: Here's is How to Trade
Immunocore: Attractive Commercial-Stage Biopharma
Bet on These 4 Biotech Stocks With Bright Prospects
Is Immunocore (IMCR) Stock Outpacing Its Medical Peers This Year?
Does Immunocore Holdings PLC Sponsored ADR (IMCR) Have the Potential to Rally 45% as Wall Street Analysts Expect?
Source: https://incomestatements.info
Category: Stock Reports